mProX™ Human RIGI Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;CT26

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

CNS Research

Related Diseases

Singleton-Merten Syndrome 2; Singleton-Merten Dysplasia

Gene ID

Human:23586

UniProt ID

Human:O95786

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RIGI (retinoic acid-inducible gene I) is a protein involved in innate immunity and the recognition of viral infections. Several studies have explored the applications of RIGI in different contexts. One study focused on ORF3c, a protein encoded by the SARS-CoV-2 virus, and its role in inhibiting innate sensing in infected cells. Another study investigated the use of lipid nanoparticle encapsulation to enhance the adjuvanticity of poly(I:C), a synthetic analogue of dsRNA that activates immune responses. Additionally, a study examined how the hepatitis C virus triggers an MDA5-mediated innate immune response by producing dsRNA without viral genome replication. Another study explored the role of ORF3c in modulating innate immunity by localizing to mitochondria and inhibiting IFN-Œ≤ production. Lastly, a study investigated how the coxsackievirus A6 protein 2C antagonizes IFN-Œ≤ production by depleting MDA5 and RIG-I. These studies highlight the diverse applications of RIGI in understanding viral infections and developing therapeutic strategies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human RIGI Stable Cell Line (S01YF-1023-PY299). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Davis (Verified Customer)

What is the role of RIGI in immune response against viral infections? Feb 24 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

RIGI plays a crucial role in the immune response against viral infections, such as avian influenza, by mediating antiviral activities and influencing gene expression. Feb 24 2020

chat Peyton Garcia (Verified Customer)

How does RIGI contribute to the regulation of antiviral responses? Jul 22 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

RIGI is involved in the regulation of antiviral responses, including the modulation of interferon alpha, which is key in controlling viral infections. Jul 22 2021

Published Data

Fig.1 Expression plasmids for FLAG-PD-L1 and HA-RIGI were introduced into HEK293T cells, and the interaction between these two proteins was subsequently confirmed upon their ectopic expression.

The interaction between endogenous and exogenous PD-L1 and RIG-I was analyzed using Co-IP in CT26 and HEK293T cells.

Ref: Zhang, Yangyang, et al. "RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination." Journal for Immunotherapy of Cancer 11.9 (2023).

Pubmed: 37758653

DOI: 10.1136/jitc-2023-007313

Research Highlights

Mueller, Martin, et al. "ORF3c is expressed in SARS-CoV-2 infected cells and suppresses immune activation by inhibiting innate sensing." bioRxiv (2023): 2023-02.
In this study, it was found that certain proteins of SARS-CoV-2 are translated from subgenomic RNAs, with the ORF3a sgRNA coding for not just ORF3a, but also for the enigmatic ORF3c, a 41-amino-acid peptide. The expression of ORF3c was observed in cells infected with SARS-CoV-2, and it was found to inhibit RIG-I and MDA5-mediated IFN-Œ≤ induction. It was also discovered that ORF3c interacts with the signaling adaptor MAVS and hinders the interaction of RIG-I with MAVS. This immunosuppressive activity was found to be present in other sarbecoviruses, including SARS-CoV. However, the delta and kappa variants of SARS-CoV-2 were detected with premature stop codons in ORF3c, suggesting that this reading frame is not essential for viral replication and may be compensated by other proteins. Moreover, disrupting ORF3c did not have a significant effect on SARS-CoV-2 replication in different cell types. This study highlights the role of ORF3c as an immune evasion factor of SARS-CoV-2, inhibiting innate sensing in infected cells.
Mueller, Martin, et al. "ORF3c is expressed in SARS-CoV-2 infected cells and suppresses immune activation by inhibiting innate sensing." bioRxiv (2023): 2023-02.
Pubmed: 37870297 DOI: 10.15252/embr.202357137

Lamoot, Alexander. et al. "Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity." Small (Weinheim an der Bergstrasse, Germany), 2023.
Poly(I:C), a synthetic analogue of dsRNA, has been recognized as a potent activator of TLR3 and RLRs, including MDA-5 and RIG-I, as pathogen recognition receptors. However, its therapeutic use as a vaccine adjuvant is limited due to susceptibility to nucleases and low uptake by immune cells. To address these issues, the researchers encapsulated poly(I:C) into lipid nanoparticles (LNPs) containing an ionizable cationic lipid, allowing for electrostatic interactions with poly(I:C). LNP-formulated poly(I:C) was found to trigger both lysosomal TLR3 and cytoplasmic RLRs, and demonstrated superior innate immune activation, compared to unformulated poly(I:C). In addition, use of LNP-formulated poly(I:C) as an adjuvant for a recombinant full-length SARS-CoV-2 spike protein resulted in potent antibody production and complete protection against viral challenge in mouse models.
Lamoot, Alexander. et al. "Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity." Small (Weinheim an der Bergstrasse, Germany), 2023.
Pubmed: 37867244 DOI: 10.1002/smll.202306892